- Home
- IBOC vs PTGX Comparison
IBOC vs PTGX Comparison
Compare IBOC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$89.53
Company Overview
Basic Information| Metric | IBOC | PTGX |
|---|---|---|
| Founded | 1966 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 5.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | IBOC | PTGX |
|---|---|---|
| Price | $69.30 | $89.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $86.44 |
| AVG Volume (30 Days) | 228.9K | ★ 898.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 5.13 | N/A |
| EPS | ★ 6.76 | 0.72 |
| Revenue | ★ $821,716,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $296.47 |
| P/E Ratio | ★ $10.25 | $124.48 |
| Revenue Growth | ★ 2.80 | N/A |
| 52 Week Low | $54.11 | $33.70 |
| 52 Week High | $73.58 | $93.25 |
Technical Indicators
Market Signals| Indicator | IBOC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 64.67 |
| Support Level | $65.96 | $83.52 |
| Resistance Level | $67.70 | $90.85 |
| Average True Range (ATR) | 1.56 | 2.63 |
| MACD | 0.49 | -0.33 |
| Stochastic Oscillator | 91.05 | 83.62 |
Price Performance
Historical Comparison IBOC
PTGX
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.